NCT00592332

Hypoglycemia Associated Autonomic Failure in Type 1 DM, Q2

Hypoglycemia Associated Autonomic Failure in Type 1 DM, Question 2

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 56 (estimated)
• Sponsor: Vanderbilt University · Academic / Other
• Sex: All
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

Alprazolam (Xanax) will blunt the body's ability to defend itself from low blood sugar.

Detailed description

Due to the fundamental importance of glucose as a cerebral fuel, a complex and redundant counterregulatory response to hypoglycemia exists in man. Some studies have shown that prior activation of GABA(A) receptors may result in blunting of counterregulatory responses during next day hypoglycemia. The Specific Aim is to determine if repeated activation of GABA(A) receptors using Alprazolam will result in blunting of neuroendocrine, ANS and metabolic counterregulatory mechanisms during next day hypoglycemia in T1DM and healthy man.

Conditions

• Type 1 Diabetes

Interventions

Type	Name	Description
DRUG	Alprazolam	1 mg alprazolam given orally 60 minutes prior to each 2 hour glucose clamp on day 1 (x2)
OTHER	control group	control group is two hyperinsulinemic glucose clamps on day 1 with no drug given.

Timeline

• Start date: 2005-06-01
• Primary completion: 2007-06-01
• Completion: 2009-06-01
• First posted: 2008-01-14
• Last updated: 2014-12-11

Locations

1 site across 1 country: United States